The SonneLuxe sonodynamic therapy for S-180 sarcoma in mice
10.3781/j.issn.1000-7431.2008.04.006
- Author:
Zhi-Yong XU
1
Author Information
1. Department of Oncology
- Publication Type:Journal Article
- Keywords:
Experimental;
Mice;
Sarcoma;
SonneLuxe;
Ultrasonic therapy
- From:
Tumor
2008;28(4):297-300
- CountryChina
- Language:Chinese
-
Abstract:
Objective: Sonodynamic therapy (SDT), using sono-sensitizer and ultrasound, is a new combined therapy for cancer treatment. The study used ultrasound to stimulate sono-sensitizer SonneLuxe, and study the tumor-killing effects of SDT on S-180 sarcoma in mice. Methods: The mice bearing S180 sarcoma were injected i. p. SonneLuxe 20 mg/kg. Six hours later, the tumor area was irradiated by 1.0 MHz ultrasound for 3 min. The mice were divided into three groups which were irradiated by ultrasound at intensity of 0.3 W/cm2, 0.6 W/cm2 and 1.2 W/cm2, respectively. The empty control, ultrasound-irradiated, and SonneLuxe-treated mice bearing S-180 sarcoma were used as different controls. The tumor size was recorded every 2 days and the tumor was weighted on the 15th day after treatment. Results: Ultrasound or SonneLuxe alone had no significant killing effect on S-180 sarcoma in mice. The proliferation of tumor was significant. SDT/SonneLuxe stimulated by ultrasound had significant inhibitory effect on the growth of S-180 sarcoma. The efficacy of SDT was enhanced accompanied with the increase in the ultrasound intensity. The adverse reaction such as photosensitive dermatitis was not observed. Conclusion: SonneLuxe/SDT had significant killing effect on S-180 sarcoma in mice. It may be a promising modality for cancer therapy.
